Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.

[1]  H. M. Petrassi,et al.  Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule. , 2017, ACS chemical biology.

[2]  Maxim N. Artyomov,et al.  End Sequence Analysis Toolkit (ESAT) expands the extractable information from single-cell RNA-seq data , 2016, Genome research.

[3]  Lisa Minor,et al.  Cell Viability Assays , 2016 .

[4]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[5]  C. Dang,et al.  MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. , 2015, Cell Metabolism.

[6]  E. Prochownik,et al.  Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids , 2015, Oncotarget.

[7]  B. Mock,et al.  Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression , 2015, ACS chemical biology.

[8]  A. Sabò,et al.  MYC: connecting selective transcriptional control to global RNA production , 2015, Nature Reviews Cancer.

[9]  Stephane Champely,et al.  Basic Functions for Power Analysis , 2015 .

[10]  M. Tomasson,et al.  Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma , 2015, Molecular Cancer Therapeutics.

[11]  Ian Collins,et al.  Photoaffinity labeling in target- and binding-site identification. , 2015, Future medicinal chemistry.

[12]  Z. Cournia,et al.  Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. , 2014, Journal of the National Cancer Institute.

[13]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[14]  M. McKeown,et al.  Therapeutic strategies to inhibit MYC. , 2014, Cold Spring Harbor perspectives in medicine.

[15]  P. Vogt,et al.  Inhibitor of MYC identified in a Kröhnke pyridine library , 2014, Proceedings of the National Academy of Sciences.

[16]  P. Nordlund,et al.  The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.

[17]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[18]  Nicolas Stransky,et al.  A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein , 2014, Molecular Cancer Therapeutics.

[19]  D. Cacchiarelli,et al.  Characterization of directed differentiation by high-throughput single-cell RNA-Seq , 2014, bioRxiv.

[20]  A. Koehler,et al.  Recent discoveries and applications involving small-molecule microarrays. , 2013, Current opinion in chemical biology.

[21]  P. Nordlund,et al.  Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.

[22]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[23]  Mercedes Robledo,et al.  MAX and MYC: a heritable breakup. , 2012, Cancer research.

[24]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[25]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[26]  John H. White,et al.  Ligand-dependent Corepressor (LCoR) Recruitment by Krüppel-like Factor 6 (KLF6) Regulates Expression of the Cyclin-dependent Kinase Inhibitor CDKN1A Gene* , 2012, The Journal of Biological Chemistry.

[27]  C. Brautigam.  Using Lamm-Equation modeling of sedimentation velocity data to determine the kinetic and thermodynamic properties of macromolecular interactions. , 2011, Methods.

[28]  Stuart L. Schreiber,et al.  Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.

[29]  Angela N Koehler,et al.  A complex task? Direct modulation of transcription factors with small molecules. , 2010, Current opinion in chemical biology.

[30]  D. Felsher.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. , 2010, Genes & cancer.

[31]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[32]  John Yu,et al.  Epithelial Cell Adhesion Molecule Regulation Is Associated with the Maintenance of the Undifferentiated Phenotype of Human Embryonic Stem Cells* , 2010, The Journal of Biological Chemistry.

[33]  Jack Taunton,et al.  Target Identification by Diazirine Photo‐Cross‐Linking and Click Chemistry , 2009, Current protocols in chemical biology.

[34]  Anna E Speers,et al.  Activity‐Based Protein Profiling (ABPP) and Click Chemistry (CC)–ABPP by MudPIT Mass Spectrometry , 2009, Current protocols in chemical biology.

[35]  Arthur J. Olson,et al.  Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function , 2009, Molecular Pharmacology.

[36]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[37]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[38]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[39]  Stuart L. Schreiber,et al.  A small molecule that binds Hedgehog and blocks its signaling in human cells , 2009, Nature chemical biology.

[40]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[41]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[42]  A. Koehler,et al.  Small-molecule microarrays as tools in ligand discovery. , 2008, Chemical Society reviews.

[43]  B. Amati,et al.  MYC degradation: deubiquitinating enzymes enter the dance , 2007, Nature Cell Biology.

[44]  Jared T Shaw,et al.  A structurally diverse library of polycyclic lactams resulting from systematic placement of proximal functional groups. , 2006, Angewandte Chemie.

[45]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Anton Blencowe,et al.  Development and application of diazirines in biological and synthetic macromolecular systems. , 2005, Soft matter.

[47]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[48]  Luc Tremblay,et al.  The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors. , 2004, Journal of molecular biology.

[49]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[50]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[51]  Pierre Lavigne,et al.  Improving the thermodynamic stability of the leucine zipper of max increases the stability of its b-HLH-LZ:E-box complex. , 2003, Journal of molecular biology.

[52]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[53]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[54]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[55]  L. Soucek,et al.  Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. , 2002, Cancer research.

[56]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[57]  B. Kempkes,et al.  Cell cycle activation by c‐myc in a Burkitt lymphoma model cell line , 2000, International journal of cancer.

[58]  R. Dennis Cook,et al.  Detection of Influential Observation in Linear Regression , 2000, Technometrics.

[59]  D. Ayer,et al.  Mlx, a Novel Max-like BHLHZip Protein That Interacts with the Max Network of Transcription Factors* , 1999, The Journal of Biological Chemistry.

[60]  U. Weidle,et al.  Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.

[61]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[62]  Wen‐Ming Yang,et al.  Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression , 1997, Cell.

[63]  Hisashi Ito,et al.  Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. , 1996, Journal of biochemistry.

[64]  E. Ziff,et al.  The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max , 1995, Molecular and cellular biology.

[65]  S. Glaser,et al.  A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients , 1994, Journal of biomolecular NMR.

[66]  S. Grzesiek,et al.  The Importance of Not Saturating H2o in Protein NMR : application to Sensitivity Enhancement and Noe Measurements , 1993 .

[67]  R. Eisenman,et al.  Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.

[68]  Paul A. Keifer,et al.  Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity , 1992 .

[69]  P. Wright,et al.  Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy , 1991 .

[70]  H. Weintraub,et al.  Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.

[71]  Maxim N. Artyomov,et al.  End Sequence Analysis ToolKit ( ESAT ) expands the extractable from single cell RNA-seq experiments , 2016 .

[72]  R. Eisenman,et al.  An overview of MYC and its interactome. , 2014, Cold Spring Harbor perspectives in medicine.

[73]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[74]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .